Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)Francisco Hernández‐Bernal, Verena L. Muzio‐González, Miladys Limonta‐Fernández et al.|EClinicalMedicine|2022Cited by 69
Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort studyPedro I. Más-Bermejo, Marta Ayala‐Ávila, Félix O. Dickinson-Meneses et al.|The Lancet Regional Health - Americas|2022Cited by 35
Cuban Abdala Vaccine: Effectiveness in Preventing Severe Disease and Death from COVID-19 in Havana, Cuba; a Cohort StudyPedro Inocencio Más-Bermejo, Marta Ayala‐Ávila, Felix Orlando Dickinson-Meneses et al.|SSRN Electronic Journal|2022Cited by 23
Combination therapy of Epidermal Growth Factor and Growth Hormone-Releasing Hexapeptide in acute ischemic stroke: a phase I/II non-blinded, randomized clinical trialFrancisco Hernández‐Bernal, Diana García-del-Barco-Herrera, Donner Estenoz-García et al.|Frontiers in Neurology|2024Cited by 6
Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)Zurina Cinza-Estévez, Y. RodriguezGuevara, Sonia Resik et al.|EClinicalMedicine|2023Cited by 6